logo-loader
viewBristol-Myers Squibb Co

Bristol-Myers falls after Citi analyst says Pfizer not interested in buying the drugmaker

New York pharma giant is also working with Harvard researchers to develop fibrotic disease treatments

Pills spilling out from a vial
The drugmaker will hold an investor event to discuss its new lung-cancer study

Bristol-Myers Squibb Co (NYSE:BMY) shares were down Thursday while Pfizer Inc. (NYSE:PFE) rose after an analyst for Citi Investment Research said a deal between the two drugmakers isn't likely to happen.

Bristol-Myers lost 2% to US$58.96, while Pfizer rose 1.7% to US$36.38 in midday trade.

Citi analyst Andrew Baum said he met with Pfizer CEO Ian Read and he had "no interest" in Bristol-Myers or other major deals right now.

"In our meeting yesterday with Pfizer’s CEO, COO and CSO, Pfizer made clear that they had no interest in BMY in the absence of transformational data or de-rating of the shares,” Baum was quoted as saying in a Citi research report shared with Streetinsider.com.

In February, Baum had laid out a scenario where Pfizer may look to buy its rival despite its large market cap.

The Citi analyst cut his price target to US$70 from US$78 after he removed a US$8 a share M&A risk premium from his target price.

"We view our newly lowered target price as conservative given the absence of contribution from CHECKMATE-9LA in 1st line non-small cell lung cancer,” Baum wrote in the report.

Investors will get a look at results next week from Bristol-Myers’s Phase 3 study of Opdivo and Yervoy in patients newly diagnosed with advanced lung cancer with high tumor mutational burden.

The New York-based drugmaker will hold an investor event to discuss the lung-cancer data on Monday at 5 p.m. CT.

Teaming up with Harvard researchers

Separately, Bristol-Myers announced on Thursday that it was working on research with the Harvard Fibrosis Network of the Harvard Stem Cell Institute to develop potential new therapies for fibrotic diseases, including fibrosis of the liver and heart.

“Bristol-Myers Squibb strives to develop transformational therapies that arrest or reverse the progression of fibrosis and restore organ function,” said Carl Decicco, head of discovery at Bristol-Myers Squibb. “We believe this collaboration will advance fibrosis research…and the development of new therapies for patients with these debilitating conditions.”

Quick facts: Bristol-Myers Squibb Co

Price: 58.59 USD

NYSE:BMY
Market: NYSE
Market Cap: $95.46 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Preveceutical announces successful preliminary evaluation of...

Preveceutical (CSE:PREV-OTCQB: PRVCF) President Mak Jawadeker joined Steve Darling from Proactive Vancouver on Skype to discuss the company successfully completing the design, synthesis and preliminary evaluation of key peptides from its scorpion venom-derived peptide research and development...

1 day, 14 hours ago

2 min read